Widya Mulyasasmita, PhD is a Sr. Principal on the Healthcare team at B Capital Group, where she focuses on investments in Biotech, Bio IT, and Innovative Med Tech. She currently serves on the board of directors at Triumvira Immunologics and OncoMyx Therapeutics, and is a board observer at HotSpot Therapeutics.
Widya joins B Capital from Red Tree Venture Capital, where she invested in and helped launch biotech and medical device companies. Prior to Red Tree, Widya was Acting Chief Business Officer at xCella Biosciences (acq. by Ligand Pharmaceuticals) and was the founding Chief Business Officer at InterVenn Biosciences. Widya was previously Director of New Ventures at Johnson & Johnson Innovation, sourcing and managing partnership deals across the pharmaceutical and medical device sectors on the US West Coast and Australia. She came to J&J from McKinsey & Company.
Widya received her B.S. in Materials Science and Bioengineering from the University of California Berkeley where she was awarded the Bioengineering Departmental Citation and her Ph.D. in Bioengineering from Stanford University where she was a Stanford Graduate Fellow and a Siebel Scholar.